Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acid

Susan M. Schima, Stephanie R. MacIejewski, Daniel E. Hilleman, Mark A. Williams, Syed M. Mohiuddin

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Importance of the field: Optimization of lipid management is a crucial aspect in the treatment of cardiovascular disease. Currently, HMG-CO reductase inhibitors (statins) are a mainstay of therapy. While this class of drugs has proven efficacy at lowering low-density lipoprotein cholesterol (LDL-C), their effects on other important lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides, are less robust. Areas covered in this review: The current paper will address the significance of these secondary targets and review currently available therapies, including a new formulation of delayed-release fenofibric acid. A comprehensive MEDLINE search (1966 to September 2009) was performed. What the reader will gain: The reader will gain a comprehensive review of the importance of secondary cholesterol targets, as well as the effectiveness of currently available therapies to address non-LDL-C. The role of the newly released fenofibric acid will also be addressed, as well as its potential use in combination therapy with a statin. Take home message: Adequate treatment of lipid parameters beyond LDL-C is an essential component in the treatment of dyslipidemia. The fibrate class of drugs has proven efficacy in improving secondary targets; however, concerns regarding severe myopathy and rhabdomyolysis have limited their combination with statins. Recently, a new fibrate derivative, fenofibric acid, has become available. Studies to date reflect a positive safety and tolerability profile when combined with statins. This may offer a new tool to address the important secondary cholesterol targets that are becoming increasingly recognized as important contributors to cardiovascular outcomes.

Original languageEnglish (US)
Pages (from-to)731-738
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Issue number5
StatePublished - Apr 1 2010

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acid'. Together they form a unique fingerprint.

Cite this